GURUFOCUS.COM » STOCK LIST » USA » NAS » Gilead Sciences Inc (NAS:GILD) » Definitions » Profitability Rank
Switch to:

Gilead Sciences Profitability Rank

: 8 (As of Jun. 2022)
View and export this data going back to 1992. Start your Free Trial

Gilead Sciences has the Profitability Rank of 8. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Gilead Sciences's Operating Margin % for the quarter that ended in Jun. 2022 was 37.68%. As of today, Gilead Sciences's Piotroski F-Score is 6.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Gilead Sciences Profitability Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Profitability Rank falls into.



Gilead Sciences Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Gilead Sciences has the Profitability Rank of 8. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Gilead Sciences's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=2359 / 6260
=37.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Gilead Sciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Gilead Sciences Inc operating margin has been in a 5-year decline. The average rate of decline per year is -8.6%.

4. Consistency of the profitability

5. Predictability Rank


Gilead Sciences Profitability Rank Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Gilead Sciences logo
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Bluestone Jeffrey director C/O PROVENTION BIO, INC. P.O. BOX 666 OLDWICK NJ 08858
Welters Anthony director
Rodriguez Javier director 601 HAWAII ST. EL SEGUNDO CA 90245
Wilfong Diane E. officer: SVP, Controller & CAO 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Horning Sandra director 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Parsey Merdad officer: Chief Medical Officer 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Dickinson Andrew D officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Mercier Johanna officer: Chief Commercial Officer 333 LAKESIDE DRIVE FOSTER CITY CA 94404
O'day Daniel Patrick director, officer: Chairman & CEO 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Hamill Laura officer: EVP, Worldwide Commercial Ops 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Manwani Harish director UNILEVER ASIA PRIVATE LTD 20 PASIR PANJANG,0622 MAPLETREE BUS CTY SINGAPORE U0 117439
Pletcher Brett A officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE FOSTER CITY X1 94404
Mchutchison John G officer: Chief Scientific Off/HeadR&D 333 LAKESIDE DRIVE FOSTER CITY X1 94404
Barton Jacqueline K director 1200 EAST CALIFORNIA BLVD PASADENA CA 91125-0072
Meyers James R officer: EVP Worldwide Commercial Ops GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404

Gilead Sciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)